| Dr Marco N Diaz, MD | |
|
96 Campus Drive, Suite 1, Scarborough, ME 04074 | |
| (207) 885-9905 | |
| (207) 396-5600 |
| Full Name | Dr Marco N Diaz |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 33 Years |
| Location | 96 Campus Drive, Scarborough, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629000302 | NPI | - | NPPES |
| 037561 | Other | ME | ANTHEM |
| 282820099 | Medicaid | ME | |
| 30200521 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD15173 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainehealth | 7517860588 | 2067 |
| Maine Medical Partners | 9335043967 | 789 |
News Archive
Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.
With a $1 million grant from the W. M. Keck Foundation, neuroscience researchers at Washington State University and the University of Massachusetts Amherst will explore whether variations in brain levels of bacterial fragments can account for life's sleep/wake and 24-hour cycles, known as circadian rhythms.
Whether or not relatives talk about the family's history of cancer significantly impacts attitudes and knowledge about genetic counseling and testing for those at moderate risk of developing breast cancer, according to a new preliminary study presented today at the American Society for Preventive Oncology meeting in Bethesda, Md.
Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).
› Verified 7 days ago
| Entity Name | St Marys Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447226584 PECOS PAC ID: 0042107120 Enrollment ID: O20040303000236 |
News Archive
Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.
With a $1 million grant from the W. M. Keck Foundation, neuroscience researchers at Washington State University and the University of Massachusetts Amherst will explore whether variations in brain levels of bacterial fragments can account for life's sleep/wake and 24-hour cycles, known as circadian rhythms.
Whether or not relatives talk about the family's history of cancer significantly impacts attitudes and knowledge about genetic counseling and testing for those at moderate risk of developing breast cancer, according to a new preliminary study presented today at the American Society for Preventive Oncology meeting in Bethesda, Md.
Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).
› Verified 7 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104921535 PECOS PAC ID: 9335043967 Enrollment ID: O20040331000274 |
News Archive
Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.
With a $1 million grant from the W. M. Keck Foundation, neuroscience researchers at Washington State University and the University of Massachusetts Amherst will explore whether variations in brain levels of bacterial fragments can account for life's sleep/wake and 24-hour cycles, known as circadian rhythms.
Whether or not relatives talk about the family's history of cancer significantly impacts attitudes and knowledge about genetic counseling and testing for those at moderate risk of developing breast cancer, according to a new preliminary study presented today at the American Society for Preventive Oncology meeting in Bethesda, Md.
Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).
› Verified 7 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.
With a $1 million grant from the W. M. Keck Foundation, neuroscience researchers at Washington State University and the University of Massachusetts Amherst will explore whether variations in brain levels of bacterial fragments can account for life's sleep/wake and 24-hour cycles, known as circadian rhythms.
Whether or not relatives talk about the family's history of cancer significantly impacts attitudes and knowledge about genetic counseling and testing for those at moderate risk of developing breast cancer, according to a new preliminary study presented today at the American Society for Preventive Oncology meeting in Bethesda, Md.
Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marco N Diaz, MD 301c Us Route One, Scarborough, ME 04074 Ph: (207) 396-8600 | Dr Marco N Diaz, MD 96 Campus Drive, Suite 1, Scarborough, ME 04074 Ph: (207) 885-9905 |
News Archive
Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.
With a $1 million grant from the W. M. Keck Foundation, neuroscience researchers at Washington State University and the University of Massachusetts Amherst will explore whether variations in brain levels of bacterial fragments can account for life's sleep/wake and 24-hour cycles, known as circadian rhythms.
Whether or not relatives talk about the family's history of cancer significantly impacts attitudes and knowledge about genetic counseling and testing for those at moderate risk of developing breast cancer, according to a new preliminary study presented today at the American Society for Preventive Oncology meeting in Bethesda, Md.
Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).
› Verified 7 days ago
Dr. Mary C. Fahrenbach, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 96 Campus Drive, Suite 1, Scarborough, ME 04074 Phone: 207-885-9905 Fax: 207-396-5600 | |
Mark A Wrona, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 51 Us Route 1 Ste I, Scarborough, ME 04074 Phone: 207-303-3300 Fax: 207-250-2139 | |
Dr. Mylan C. Cohen, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 96 Campus Drive, Suite 1, Scarborough, ME 04074 Phone: 207-885-9905 Fax: 207-396-5600 | |
Mirle A Kellett, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 96 Campus Dr, Suite 1, Scarborough, ME 04074 Phone: 207-396-5611 | |
Dr. Warren D Alpern, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 96 Campus Dr, Suite 1, Scarborough, ME 04074 Phone: 207-396-5611 | |
Dr. Eleni Nicole Nackos, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Campus Dr Unit 108, Scarborough, ME 04074 Phone: 207-303-3300 Fax: 207-250-2139 | |
Susan Miesfeldt, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Campus Drive, Suite 110, Scarborough, ME 04074 Phone: 207-396-7678 Fax: 207-396-8766 |